Comparative Pharmacology
Head-to-head clinical analysis: BENZONATATE versus VICKS FORMULA 44.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZONATATE versus VICKS FORMULA 44.
BENZONATATE vs VICKS FORMULA 44
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.
VICKS FORMULA 44 contains dextromethorphan (NMDA receptor antagonist and sigma-1 receptor agonist; suppresses cough by acting on the medullary cough center) and doxylamine (first-generation antihistamine; H1-receptor antagonist; anticholinergic and sedative effects).
100 mg to 200 mg orally three times daily as needed for cough.
VICKS FORMULA 44 is a combination product containing dextromethorphan (cough suppressant) and doxylamine (antihistamine). The typical adult dose is 30 mg dextromethorphan/6.25 mg doxylamine (15 mL) orally every 6 hours as needed for cough and cold symptoms, not to exceed 4 doses per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 3–8 hours in adults; prolonged in hepatic impairment.
Dextromethorphan: 3-6 hours (extensive metabolizers), up to 24 hours (poor metabolizers); doxylamine: 10-12 hours. Clinically, half-life may be prolonged in elderly, hepatic impairment, or CYP2D6 poor metabolizers.
Primarily renal excretion of metabolites; unchanged benzonatate is negligible. Fecal elimination accounts for <5%. Biliary excretion is minimal.
Renal excretion of unchanged drug and metabolites (dextromethorphan and doxylamine): dextromethorphan is extensively metabolized; <10% excreted unchanged. Doxylamine: ~60% excreted renally as unchanged and metabolites.
Category A/B
Category C
Antitussive
Antitussive